U.S. District Court Upholds Validity of CINVANTI® Patents

HRTX 12.03.2024

Full Press ReleaseSEC FilingsOur HRTX Tweets

About Gravity Analytica

Recent News

  • 12.23.2024 - Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
  • 12.03.2024 - U.S. District Court Upholds Validity of CINVANTI® Patents
  • 11.12.2024 - Heron Therapeutics Q3 2024 Conference Call

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.23.2024 - 8-K Current report
  • 12.23.2024 - EX-99.1 EX-99.1

— Court Rules in Favor of Heron inPatent Lawsuit Against Fresenius Kabi USA, LLC—

SAN DIEGO,Dec. 3, 2024/PRNewswire/ --Heron Therapeutics, Inc.(Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that theU.S. District Court for the District of Delawareruled in Heron's favor in the Company's patent litigation againstFresenius Kabi USA, LLCwith respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron'sU.S.Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius' proposed generic product.

The district court decision concludes the litigation initiated inJuly 2022in response to Fresenius' submission of an Abbreviated New Drug Application with theU.S. Food and Drug Administrationseeking approval of a generic version of CINVANTI®. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI® until after the expiration of the patents in 2035. This decision is subject to appeal.

"We are pleased with this anticipated result of the proceeding and will continue to vigorously defend the CINVANTI® patent estate in the future," said Craig Collard, Chief Executive Officer of Heron. "The team at Heron takes great pride in the result of our successful history of developing injectable products, which is demonstrated by the strength of our intellectual property and the performance of our innovative drugs like CINVANTI® in serving patients with serious unmet needs."

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visitwww.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. Therefore, you should not place undue reliance on forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira DuarteExecutive Vice President, Chief Financial OfficerHeron Therapeutics, Inc.iduarte@herontx.com858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/us-district-court-upholds-validity-of-cinvanti-patents-302321651.html

SOURCEHeron Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com